Table 1.
Total Subjects by Study and Treatment
| Study (Reference) | Arm | Total (n) | Age (yr) (Mean ± SD) | Age < 30 (n) | Age ≥ 30 (n) |
|---|---|---|---|---|---|
| BAGS (17) | Albuterol | 120 | 28.4 ± 8.6 | 73 | 47 |
| Placebo | 122 | 29.1 ± 9.3 | 76 | 46 | |
| SOCS (18) | Placebo | 52 | 30.7 ± 10.4 | 28 | 24 |
| Salmeterol | 49 | 31.1 ± 10.2 | 26 | 23 | |
| ICS | 49 | 31.3 ± 11.3 | 28 | 21 | |
| SLIC (19)* | Placebo + ICS (pretaper) | 14 | 33.8 ± 13.0 | 5 | 9 |
| Placebo only (post-taper) | 4 | 39.6 ± 18.7 | 1 | 3 | |
| Salmeterol + ICS (pretaper) | 43 | 33.5 ± 10.9 | 20 | 23 | |
| Salmeterol + ICS (sham taper) | 72 | 36.3 ± 12.4 | 26 | 46 | |
| Salmeterol only (post-taper) | 24 | 35.7 ± 11.8 | 11 | 13 | |
| DICE (20) | Placebo | 8 | 31.9 ± 12.9 | 5 | 3 |
| ICS | 100 | 30.6 ± 8.6 | 58 | 42 | |
| MICE (21) | ICS | 29 | 29.6 ± 7.2 | 18 | 11 |
| BARGE (22)* | Albuterol | 29 | 30.3 ± 6.4 | 13 | 16 |
| Placebo | 39 | 29.5 ± 9.7 | 24 | 15 | |
| IMPACT (23) | Budesonide | 70 | 32.7 ± 9.3 | 33 | 37 |
| Placebo | 68 | 32.2 ± 10.2 | 36 | 32 | |
| Zafirlukast | 69 | 33.4 ± 10.7 | 29 | 40 | |
| SMOG (24)* | Montelukast | 14 | 27.2 ± 3.5 | 12 | 2 |
| Beclomethasone | 8 | 25.4 ± 5.1 | 7 | 1 | |
| SLIMSIT (25)* | Salmeterol + montelukast | 91 | 34.2 ± 10.2 | 33 | 58 |
| Salmeterol + beclomethasone | 69 | 33.7 ± 10.6 | 29 | 40 | |
| PRICE (26) | Placebo | 27 | 32.3 ± 9.4 | 12 | 15 |
| ICS | 30 | 32.7 ± 9.4 | 17 | 13 | |
| Total | 1,200 | 31.7 ± 10.1 | 621 | 579 |
Definition of abbreviation: ICS = inhaled corticosteroid.
All subjects were unique across studies.
*
SLIC, BARGE, SMOG, and SLIMSIT were either crossover designs or designs that used multiple treatments over several study periods.